Concert Pharmaceuticals Inc. (CNCE) 12.76 $CNCE
Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer
Business Wire - Wed Feb 04, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert's product development strategy and operations and will have responsibility for all preclinical, clinical and manufacturing activities.
CNCE: 12.76 (-0.46)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 9:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 22, 2014.
CNCE: 12.76 (-0.46)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:39PM CST
Jazz Pharmaceuticals (JAZZ) shares slipped after announcing that JZP-386 was not administered in the first phase I study due to a technical dosing issue.
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), JAZZ: 169.69 (+6.89), CNCE: 12.76 (-0.46)
Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee
Business Wire - Wed Dec 10, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Thomas G. Auchincloss, Jr. will join its Board of Directors and serve as the independent chair of the Board's Audit Committee, effective immediately. Mr. Auchincloss replaces Helmut Schuhsler as Chair of the Audit Committee. Dr. Schuhsler will remain a member of Concert's Board of Directors.
CNCE: 12.76 (-0.46), MBLX: 0.44 (-0.02)
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
Business Wire - Tue Dec 09, 7:30AM CST
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that Phase 1 clinical data generated to date supports completing the Phase 1 evaluation of JZP-386 at the originally planned highest dose, which was not administered in the first Phase 1 trial due to a technical dosing issue. The existing Phase 1 clinical data was generated in a first-in-human trial evaluating the safety, pharmacokinetics, and pharmacodynamics of JZP-386; enrollment was completed in the third quarter. A second Phase 1 trial evaluating JZP-386 at the originally planned highest dose is expected to be initiated in the first quarter of 2015, with data expected in the second quarter of 2015.
JAZZ: 169.69 (+6.89), CNCE: 12.76 (-0.46)
Seizures Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Mon Dec 08, 6:30PM CST
The report "Seizures Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/seizures-pip...eport.html .
PFE: 34.64 (-0.23), ACOR: 36.14 (-0.51), CNCE: 12.76 (-0.46), NVS: 102.20 (-0.17)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.42 (+0.15), JNJ: 99.62 (+1.18), LLY: 70.56 (+0.03), CNCE: 12.76 (-0.46), OMER: 20.63 (+0.13)
InsiderInsights.com Daily Round Up 11/20/14: NES, OPK, OKS, PAH
InsiderInsights - at Seeking Alpha - Mon Nov 24, 2:04PM CST
NES: 3.52 (+0.13), RAX: 50.01 (+0.24), JAH: 51.18 (+0.18), LNG: 74.48 (+0.90), MRD: 18.66 (+0.23), PAH: 22.68 (+0.14), AON: 100.56 (-0.18), SGM: 10.68 (+0.08), CLI: 19.81 (-0.02), CNCE: 12.76 (-0.46), VSAR: 18.04 (-0.55), OPK: 13.80 (-0.28), HZNP: 16.84 (-0.41), CATY: 26.14 (+0.42), IMH: 9.97 (+0.10), OKS: 45.47 (+0.07), GRPN: 7.97 (+0.51), SFXE: 3.49 (+0.01), SCHW: 29.13 (-0.83)
Flamel Technologies: A Turnaround Story With Lots Of Upside
Small Pharma Analyst - at Seeking Alpha - Fri Nov 21, 12:05PM CST
FLML: 14.15 (+0.15), CNCE: 12.76 (-0.46)
Concert Pharmaceuticals' (CNCE) CEO Roger Tung on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:59AM CST
CNCE: 12.76 (-0.46)
Concert Pharma ups revenues 529% in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:53AM CST
CNCE: 12.76 (-0.46)
Concert Pharma beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:14AM CST
CNCE: 12.76 (-0.46)
Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Update on CTP-354 Program
Business Wire - Wed Nov 12, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2014 and provided an update on its pipeline and CTP-354.
CNCE: 12.76 (-0.46)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 4:30PM CST
ELOS: 10.16 (+0.07), WUBA: 42.05 (+3.79), SEAS: 18.83 (+0.03), EZCH: 21.41 (+0.14), PLUG: 3.15 (unch), MRKT: 26.14 (-0.67), M: 64.32 (-0.34), BZH: 17.13 (-0.04), CAE: 12.21 (+0.11), CSIQ: 28.84 (-0.30), ENR: 138.49 (+3.42), ADT: 38.21 (+0.11), CNCE: 12.76 (-0.46), ECA: 14.07 (+0.37), RICE: 19.13 (-0.22), MTLS: 8.17 (+0.04), AG: 6.08 (+0.17), ARMK: 30.54 (-0.18), MGAM: 36.44 (-0.01), SLW: 22.76 (+0.34), PF: 36.18 (-0.21), MTOR: 14.33 (+0.38), ROK: 117.90 (+1.02), FLO: 21.68 (+0.38), DWSN: 6.89 (-0.42)
Concert Pharmaceuticals to Present at Stifel 2014 Healthcare Conference on November 18, 2014
Business Wire - Tue Nov 11, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Stifel 2014 Healthcare Conference, November 18, 2014 at 1:50 p.m. EST at The New York Palace Hotel in New York City.
CNCE: 12.76 (-0.46)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 14.40 (+0.82), LLY: 70.56 (+0.03), CNCE: 12.76 (-0.46), OPK: 13.80 (-0.28), AZN: 69.96 (+0.20), ALXN: 182.29 (+6.02), ICPT: 209.12 (+7.12), NPSP: 45.88 (+0.03), XLRN: 38.02 (+0.07)
Concert Pharmaceuticals to Report Third Quarter 2014 Results on November 12, 2014
Business Wire - Wed Nov 05, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2014 financial results on Wednesday, November 12, 2014 before the financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EST to discuss third quarter financial results and provide a business and clinical pipeline update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
CNCE: 12.76 (-0.46)
Concert Pharmaceuticals Announces Positive CTP-354 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:04PM CDT
Concert Pharmaceuticals, Inc. (CNCE) recently announced encouraging data from a phase I study on CTP-354.
AVNR: 16.96 (unch), SHPG: 239.82 (+6.11), JAZZ: 169.69 (+6.89), CNCE: 12.76 (-0.46)
Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer
Business Wire - Wed Feb 04, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert's product development strategy and operations and will have responsibility for all preclinical, clinical and manufacturing activities.
CNCE: 12.76 (-0.46)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 9:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 22, 2014.
CNCE: 12.76 (-0.46)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:39PM CST
Jazz Pharmaceuticals (JAZZ) shares slipped after announcing that JZP-386 was not administered in the first phase I study due to a technical dosing issue.
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), JAZZ: 169.69 (+6.89), CNCE: 12.76 (-0.46)
Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee
Business Wire - Wed Dec 10, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Thomas G. Auchincloss, Jr. will join its Board of Directors and serve as the independent chair of the Board's Audit Committee, effective immediately. Mr. Auchincloss replaces Helmut Schuhsler as Chair of the Audit Committee. Dr. Schuhsler will remain a member of Concert's Board of Directors.
CNCE: 12.76 (-0.46), MBLX: 0.44 (-0.02)
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
Business Wire - Tue Dec 09, 7:30AM CST
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that Phase 1 clinical data generated to date supports completing the Phase 1 evaluation of JZP-386 at the originally planned highest dose, which was not administered in the first Phase 1 trial due to a technical dosing issue. The existing Phase 1 clinical data was generated in a first-in-human trial evaluating the safety, pharmacokinetics, and pharmacodynamics of JZP-386; enrollment was completed in the third quarter. A second Phase 1 trial evaluating JZP-386 at the originally planned highest dose is expected to be initiated in the first quarter of 2015, with data expected in the second quarter of 2015.
JAZZ: 169.69 (+6.89), CNCE: 12.76 (-0.46)
Seizures Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Mon Dec 08, 6:30PM CST
The report "Seizures Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/seizures-pip...eport.html .
PFE: 34.64 (-0.23), ACOR: 36.14 (-0.51), CNCE: 12.76 (-0.46), NVS: 102.20 (-0.17)
Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.42 (+0.15), JNJ: 99.62 (+1.18), LLY: 70.56 (+0.03), CNCE: 12.76 (-0.46), OMER: 20.63 (+0.13)
InsiderInsights.com Daily Round Up 11/20/14: NES, OPK, OKS, PAH
InsiderInsights - at Seeking Alpha - Mon Nov 24, 2:04PM CST
NES: 3.52 (+0.13), RAX: 50.01 (+0.24), JAH: 51.18 (+0.18), LNG: 74.48 (+0.90), MRD: 18.66 (+0.23), PAH: 22.68 (+0.14), AON: 100.56 (-0.18), SGM: 10.68 (+0.08), CLI: 19.81 (-0.02), CNCE: 12.76 (-0.46), VSAR: 18.04 (-0.55), OPK: 13.80 (-0.28), HZNP: 16.84 (-0.41), CATY: 26.14 (+0.42), IMH: 9.97 (+0.10), OKS: 45.47 (+0.07), GRPN: 7.97 (+0.51), SFXE: 3.49 (+0.01), SCHW: 29.13 (-0.83)
Flamel Technologies: A Turnaround Story With Lots Of Upside
Small Pharma Analyst - at Seeking Alpha - Fri Nov 21, 12:05PM CST
FLML: 14.15 (+0.15), CNCE: 12.76 (-0.46)
Concert Pharmaceuticals' (CNCE) CEO Roger Tung on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:59AM CST
CNCE: 12.76 (-0.46)
Concert Pharma ups revenues 529% in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:53AM CST
CNCE: 12.76 (-0.46)
Concert Pharma beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:14AM CST
CNCE: 12.76 (-0.46)
Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Update on CTP-354 Program
Business Wire - Wed Nov 12, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2014 and provided an update on its pipeline and CTP-354.
CNCE: 12.76 (-0.46)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 4:30PM CST
ELOS: 10.16 (+0.07), WUBA: 42.05 (+3.79), SEAS: 18.83 (+0.03), EZCH: 21.41 (+0.14), PLUG: 3.15 (unch), MRKT: 26.14 (-0.67), M: 64.32 (-0.34), BZH: 17.13 (-0.04), CAE: 12.21 (+0.11), CSIQ: 28.84 (-0.30), ENR: 138.49 (+3.42), ADT: 38.21 (+0.11), CNCE: 12.76 (-0.46), ECA: 14.07 (+0.37), RICE: 19.13 (-0.22), MTLS: 8.17 (+0.04), AG: 6.08 (+0.17), ARMK: 30.54 (-0.18), MGAM: 36.44 (-0.01), SLW: 22.76 (+0.34), PF: 36.18 (-0.21), MTOR: 14.33 (+0.38), ROK: 117.90 (+1.02), FLO: 21.68 (+0.38), DWSN: 6.89 (-0.42)
Concert Pharmaceuticals to Present at Stifel 2014 Healthcare Conference on November 18, 2014
Business Wire - Tue Nov 11, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Stifel 2014 Healthcare Conference, November 18, 2014 at 1:50 p.m. EST at The New York Palace Hotel in New York City.
CNCE: 12.76 (-0.46)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 14.40 (+0.82), LLY: 70.56 (+0.03), CNCE: 12.76 (-0.46), OPK: 13.80 (-0.28), AZN: 69.96 (+0.20), ALXN: 182.29 (+6.02), ICPT: 209.12 (+7.12), NPSP: 45.88 (+0.03), XLRN: 38.02 (+0.07)
Concert Pharmaceuticals to Report Third Quarter 2014 Results on November 12, 2014
Business Wire - Wed Nov 05, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2014 financial results on Wednesday, November 12, 2014 before the financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EST to discuss third quarter financial results and provide a business and clinical pipeline update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
CNCE: 12.76 (-0.46)
Concert Pharmaceuticals Announces Positive CTP-354 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:04PM CDT
Concert Pharmaceuticals, Inc. (CNCE) recently announced encouraging data from a phase I study on CTP-354.
AVNR: 16.96 (unch), SHPG: 239.82 (+6.11), JAZZ: 169.69 (+6.89), CNCE: 12.76 (-0.46)
